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rug-Eluting Stents for
aphenous Vein Graft Lesions
he Limits of Evidence*
ohn A. Bittl, MD
cala, Florida
rug-eluting stents (DES) have been a major advance in
nterventional cardiology, but evidence for using these
evices does not exist for all types of lesions or for all subsets
f patients. One area where data have been lacking is the
ndication of diseased aortocoronary saphenous vein grafts
SVGs).
A randomized trial (1) reported in this issue of the Journal
arrows the evidence gap. In the SOS (Stenting Of Saphe-
ous Vein Grafts) trial (1), the primary end point of binary
estenosis was lower (9% vs. 51%, p  0.0001) after the use
f paclitaxel-eluting stents than after the use of similar
are-metal stents for lesions in SVGs of diameters of 2.5 to
.0 mm. An important finding from this 80-patient study
as that all-cause mortality was similar between the 2
roups at a median follow-up of 1.5 years.
See page 919
revious randomized study. Concerns about late mortal-
ty after using DES for SVG lesions emerged in an earlier
andomized study. The initial publication of the RRISC
Reduction of Restenosis in Saphenous Vein Grafts with
ypher Sirolimus-Eluting Stents) trial (2) reported that the
rimary end point of late loss was lower after the use of
irolimus-eluting stents than after the use of bare-metal
tents, but a follow-up study found unfavorable clinical
utcomes (3). After a median follow-up of 32 months, 11
eaths occurred in the group receiving sirolimus-eluting
tents (29%) but none occurred in the group receiving
are-metal stents (p  0.001). Three deaths were sudden,
nd 1 was caused by stent thrombosis (3). Although the
ndings added to concerns about the long-term safety of
ES, the imbalance was likely caused by the play of chance
n a 75-patient study neither adequately powered nor
rospectively designed to show a mortality difference. In any
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or theS
merican College of Cardiology.
From the Ocala Heart Institute, Munroe Regional Medical Center, Ocala, Florida.ase, the reversal of conclusions from the study (2,3)
upported the recurring theme that all medical knowledge,
ven that from a single trial, is provisional.
ohort studies. No evidence of harm has appeared in a
ecent review (4) of 8 retrospective cohort studies of DES
or SVG lesions, although results were mixed. Two newer
eports have continued the trend of presenting null or
ositive results. Gioia et al. (5) reported that 106 patients
reated with DES for SVG lesions had similar rates of
vent-free survival (81% vs. 82%, p  0.9), target vessel
evascularization (14% vs. 14%, p  1.0), or death (6% vs.
%, p  1.0) at 2 years, compared with 119 patients treated
ith bare-metal stents. Brodie et al. (6) reported that 825
atients treated with DES for SVG lesions had lower rates
f target vessel revascularization at 9 months than 361
atients with bare-metal stents (7.5% vs. 9.4%, p  0.05).
ersistent challenge of restenosis. Bare-metal stents,
hich have been widely used to treat SVG lesions, have
roduced only limited evidence of efficacy in randomized
rials. The landmark SAVED (Saphenous Vein De Novo)
rial generated mixed results (7). The primary end point of
inary restenosis was not reduced by stenting compared
ith balloon angioplasty (37% vs. 46%, p  0.24), although
he component of the composite clinical outcomes at 240
ays having the largest trend toward a benefit was target
esion revascularization (17% vs. 26%, p  0.09).
iologic plausibility. To achieve better outcomes than
are-metal stents, DES should exert antiproliferative effects
ithin the heterogeneous milieu of diseased SVGs. Con-
entional wisdom states that atherosclerosis found in SVGs
lder than 3 years is similar to that found in native coronary
rteries. However, SVG atheromas contain fewer fibrocol-
agenous components than native-vessel atheromas. Fibrous
aps, common in native-vessel disease, are poorly developed
r absent in SVG atheromas (8), explaining the tendency for
mbolization during stenting and supporting the use of
mbolic protection devices.
The histology of restenotic lesions, occurring 5 months to
years after bare-metal stent implantation in SVGs an
verage of 11 years after surgery (similar to the age of grafts
n the current study [1]), shows that the neointima extend-
ng from the stent struts to the lumen contains at least
oderate numbers of smooth muscle cells (9). In some cases
here stents are in contact with an underlying plaque
ontaining a necrotic core, no healing is observed. Instead,
he friable atherosclerotic plaque and thrombus may pro-
apse through stent struts (9).
Intravascular brachytherapy, analogous to DES in its goal
f reducing cellular proliferation but never approved for use
n SVGs, resulted in lower rates of restenosis at 6 months
han placebo (21% vs. 44%, p 0.005) in a randomized trial
f 120 patients with in-stent restenosis in SVGs (10).
lacement of DES also has the theoretical potential to
educe in-segment restenosis after primary treatment of
VG lesions, but technical failings such as geographical
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DES for SVG Lesions March 17, 2009:929–30iss, plaque prolapse, and progression of nontarget lesions
ould mitigate the clinical benefit.
ontarget progression. Patients undergoing stenting of
VG lesions are at increased risk of events caused by the
rogression of nontarget lesions. After implantation of
irolimus-eluting stents, adverse cardiac events have been
ore than twice as high after treatment of SVG lesions than
fter treatment of native-vessel disease (11). Events after 12
onths have resulted more commonly from progression of
isease at untreated sites than at treated vein graft sites (12).
ortality rates have tended to be much higher after SVG
ntervention than after native-vessel intervention. In the
andmark stent trials, the mortality rate of 7% at 6 months
fter SVG stenting (7) was higher than the mortality rates of
.8% at 7 months (13) and 1.5% at 240 days after native-
essel stenting (14).
mplications of current trials. The 2 small but well-
erformed mechanistic trials (1,2) have shown that DES
roduce better primary angiographic end points than bare-
etal stents. This does not mean that DES will produce better
linical outcomes, achieve better angiographic outcomes for all
atients with SVG lesions, or even achieve the same angio-
raphic outcomes at different times after stent implantation.
The available evidence suggests that DES are a modest
dvance for treating patients with SVG lesions (by way of
ontrast, several large randomized trials have demonstrated
hat embolic protection devices have been a major advance).
he decision to use DES for SVG lesions remains multi-
aceted and depends on such factors as graft size, predicted
dherence to prolonged dual antiplatelet therapy, and the
ncreasingly dominant role of patient preference.
The use of DES for SVG lesions is part of the larger
phere of evidence-based cardiovascular medicine in which,
s articulated by Dr. Robert Califf, only 15% of guidelines
rom the American Heart Association and the American
ollege of Cardiology are based on solid scientific evidence
15). The universal call for additional research has already
een made (4). The process of continual assessment, reeval-
ation, and integration of trial data defines a world that
ever stands still.
eprint requests and correspondence: Dr. John A. Bittl, 13013
ighway 475, Ocala, Florida 34480. E-mail: jabittl@mac.com.
KEFERENCES
1. Brilakis ES, Lichtenwalter C, de Lemos JA, et al. A randomized
controlled trial of a paclitaxel-eluting stent versus a similar bare-metal
stent in saphenous vein graft lesions: the SOS (Stenting Of Saphenous
Vein Grafts) trial. J Am Coll Cardiol 2009;53:919–28.
2. Vermeersch P, Agostoni P, Verheye S, et al. Randomized double-
blind comparison of sirolimus-eluting stent versus bare-metal stent
implantation in diseased saphenous vein grafts: six-month angio-
graphic, intravascular ultrasound, and clinical follow-up of the RRISC
Trial. J Am Coll Cardiol 2006;48:2423–31.
3. Vermeersch P, Agostoni P, Veryheye S, et al. Increased late mortality
after sirolimus-eluting stents versus bare-metal stents in diseased
saphenous vein grafts: results from the randomized DELAYED
RRISC trial. J Am Coll Cardiol 2007;50:261–70.
4. Brilakis ES, Berger PB. Should bare metal or drug-eluting stents be
used during PCI of saphenous vein graft lesions: waiting for Godot?
Catheter Cardiovasc Interv 2008;72:815–8.
5. Gioia G, Bennassi A, Mohendra R, Chowdhury K, Massood I,
Matthai W. Lack of clinical long-term benefit with the use of a drug
eluting stent compared to use of a bare metal stent in saphenous vein
grafts. Catheter Cardiovasc Interv 2008;72:13–20.
6. Brodie BR, Stuckey T, DowneyW, et al. Outcomes and complications
with off-label use of drug-eluting stents: results from STENT (Stra-
tegic Transcatheter Evaluation of New Therapies) Group. J Am Coll
Cardiol Interv 2008;1:405–15.
7. Savage MP, Douglas JS, Fischman DL, et al. Stent placement
compared with balloon angioplasty for obstructed coronary bypass
grafts. N Engl J Med 1997;337:740–7.
8. Ratliff NB, Myles JL. Rapidly progressive atherosclerosis in aortocoro-
nary saphenous vein grafts: possible immune-mediated disease. Arch
Pathol Lab Med 1989;113:772–6.
9. Ribichini F, Pugno F, Ferrero V, et al. Long-term histological and
immunohistochemical findings in human venous aorto-coronary by-
pass grafts. Clin Sci (Lond) 2008;114:211–20.
0. Waksman R, Ajani AE, White RL, et al. Intravascular gamma
radiation for in-stent restenosis in saphenous-vein bypass grafts.
N Engl J Med 2002;346:1194–9.
1. Hoffman R, Hamm C, Nienaber CA, et al. Implantation of sirolimus-
eluting stents in saphenous vein grafts is associated with high clinical
follow-up event rates compared with treatment of native vessels.
Coron Artery Dis 2007;18:559–64.
2. Ellis SG, Brener SJ, DeLuca S, et al. Late myocardial ischemic events
after saphenous vein graft intervention—importance of initially “non-
significant” vein graft lesions. Am J Cardiol 1997;79:1460–4.
3. Serruys P, de Jaegere P, Kiemeneij F, et al. A comparison of
balloon-expandable-stent implantation with balloon angioplasty in
patients with coronary artery disease. N Engl J Med 1994;331:489–95.
4. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison
of coronary-stent placement and balloon angioplasty in the treatment
of coronary artery disease. N Engl J Med 1994;331:496–501.
5. Kolata G. New arena for testing of drugs: real world. New York Times.
New York edition, vol. CLVIII, 2008:D1.ey Words: atherosclerosis y randomized trials y restenosis.
